MEDICAL RESEARCH AND GENETIC RESOURCES MANAGEMENT: THE CASE OF TAXOL

KELLY A. Day, George B Frisvold

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Commercial development of the anti‐cancer drug taxol has involved a complex set of interlocking research agreements. This paper explores the implications of such agreements and discusses diverse policy issues surrounding taxol development. Among these are forest management, species preservation, intellectual property rights, and the economics of biomedical research. Advances in genetic research increasingly have linked natural resource and technology policy issues. Institutional innovations in public/private research arrangements play a vital role in biotechnology development but are poorly understood. Policymakers need formal analyses of such agreements in order to evaluate complex research programs.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalContemporary Economic Policy
Volume11
Issue number3
DOIs
StatePublished - 1993
Externally publishedYes

ASJC Scopus subject areas

  • Business, Management and Accounting(all)
  • Economics and Econometrics
  • Public Administration

Fingerprint Dive into the research topics of 'MEDICAL RESEARCH AND GENETIC RESOURCES MANAGEMENT: THE CASE OF TAXOL'. Together they form a unique fingerprint.

Cite this